Nuclera (NUCLERA NUCLEICS LTD.)
History
| Year | Detail |
|---|---|
| 2013 | Nuclera was founded by Michael Chen, Jiahao Huang, and Gordon Herling-McInroy at the University of Cambridge. While writing their dissertations, they identified protein inaccessibility as the number one obstacle and a key bottleneck in biology. |
| 2021 | The company acquired E Ink's digital microfluidic technology to deliver desktop protein and gene “bioprinters” for researchers in human health, agriculture, and other markets. |
| 2022 | The company expanded its offerings portfolio by establishing a new subsidiary in Boston, U.S., to deliver Nuclera’s protein desktop bioprinter to biotherapeutics, agribiotech, and other regional markets. |
| 2023 | Nuclera partnered with Google to serve the life science community by offering a higher probability of identifying de facto optimal target proteins and, in turn, extensively improving drug discovery programs. |
| 2024 | The company partnered with Sharp Life Science and licensed its digital microfluidic intellectual property portfolio for AI/ML-enabled cell-free and cell-based protein design and biomanufacturing. |